Stock Track | WUXI BIO Soars 16% on Plans to Sell Units Amid US Restrictions

Stock Track10-04

Shares of WUXI BIO (02269) soared 16.33% to close at HK$78.50 on Thursday, amid news that its subsidiary WuXi Biologics (Cayman) and affiliate WuXi AppTech are planning to sell certain operations in response to restrictions imposed by the United States.

WUXI BIO, a leading global provider of innovative biologic drug development and manufacturing services, saw its stock surge to a new 52-week high on the Hong Kong Stock Exchange. The rally was driven by reports that WuXi Biologics (Cayman) and WuXi AppTech are offloading their cell and gene therapy manufacturing unit, WuXi Advanced Therapies.

The move comes as the US government has tightened scrutiny on Chinese companies involved in biotechnology and advanced manufacturing due to national security concerns. By divesting these operations, WUXI BIO aims to address potential regulatory hurdles and mitigate risks associated with its US business.

Analysts view the divestment plan as a strategic move by WUXI BIO to protect its core business and maintain its strong foothold in the global biopharmaceutical market. The company's commitment to compliance and adaptability in the face of geopolitical tensions has been well-received by investors, as evidenced by the significant stock price surge.

The Hong Kong Stock Exchange saw broad gains on Thursday, with the Hang Seng Index climbing 2.82% to 22,736.87 points, boosted by a rally in tech and e-commerce stocks. WUXI BIO's strong performance contributed to the positive sentiment in the market.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1173776535?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-10-04 16:42","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1173776535","market":"us","top_or_hot":-1,"title":"Stock Track | WUXI BIO Soars 16% on Plans to Sell Units Amid US Restrictions","media":"Stock Track","content":"<p>Shares of WUXI BIO (02269) soared 16.33% to close at HK$78.50 on Thursday, amid news that its subsidiary WuXi Biologics (Cayman) and affiliate WuXi AppTech are planning to sell certain operations in response to restrictions imposed by the United States.</p>\n\n<p>WUXI BIO, a leading global provider of innovative biologic drug development and manufacturing services, saw its stock surge to a new 52-week high on the Hong Kong Stock Exchange. The rally was driven by reports that WuXi Biologics (Cayman) and WuXi AppTech are offloading their cell and gene therapy manufacturing unit, WuXi Advanced Therapies.</p>\n\n<p>The move comes as the US government has tightened scrutiny on Chinese companies involved in biotechnology and advanced manufacturing due to national security concerns. By divesting these operations, WUXI BIO aims to address potential regulatory hurdles and mitigate risks associated with its US business.</p>\n\n<p>Analysts view the divestment plan as a strategic move by WUXI BIO to protect its core business and maintain its strong foothold in the global biopharmaceutical market. The company's commitment to compliance and adaptability in the face of geopolitical tensions has been well-received by investors, as evidenced by the significant stock price surge.</p>\n\n<p>The Hong Kong Stock Exchange saw broad gains on Thursday, with the Hang Seng Index climbing 2.82% to 22,736.87 points, boosted by a rally in tech and e-commerce stocks. WUXI BIO's strong performance contributed to the positive sentiment in the market.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | WUXI BIO Soars 16% on Plans to Sell Units Amid US Restrictions</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | WUXI BIO Soars 16% on Plans to Sell Units Amid US Restrictions\n</h2>\n\n<h4 class=\"meta\">\n\n2024-10-04 16:42 北京时间&nbsp;&nbsp;&nbsp;<strong>Stock Track</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Shares of WUXI BIO (02269) soared 16.33% to close at HK$78.50 on Thursday, amid news that its subsidiary WuXi Biologics (Cayman) and affiliate WuXi AppTech are planning to sell certain operations in ...</p>\n\n<a href=\"\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02269","symbol_name":"药明生物","start_time":0,"source_url":"","article_id":"1173776535","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1173776535","pubTimestamp":1728031369,"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of WUXI BIO  soared 16.33% to close at HK$78.50 on Thursday, amid news that its subsidiary WuXi Biologics  and affiliate WuXi AppTech are planning to sell certain operations in response to restrictions imposed by the United States.WUXI BIO, a leading global provider of innovative biologic drug development and manufacturing services, saw its stock surge to a new 52-week high on the Hong Kong Stock Exchange. The rally was driven by reports that WuXi Biologics  and WuXi AppTech are offloadin","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02269":"药明生物"},"translate_title":"股票赛道药明生物因计划在美国限制下出售单位而飙升16%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02269":1},"content_text":"Shares of WUXI BIO (02269) soared 16.33% to close at HK$78.50 on Thursday, amid news that its subsidiary WuXi Biologics (Cayman) and affiliate WuXi AppTech are planning to sell certain operations in response to restrictions imposed by the United States.\nWUXI BIO, a leading global provider of innovative biologic drug development and manufacturing services, saw its stock surge to a new 52-week high on the Hong Kong Stock Exchange. The rally was driven by reports that WuXi Biologics (Cayman) and WuXi AppTech are offloading their cell and gene therapy manufacturing unit, WuXi Advanced Therapies.\nThe move comes as the US government has tightened scrutiny on Chinese companies involved in biotechnology and advanced manufacturing due to national security concerns. By divesting these operations, WUXI BIO aims to address potential regulatory hurdles and mitigate risks associated with its US business.\nAnalysts view the divestment plan as a strategic move by WUXI BIO to protect its core business and maintain its strong foothold in the global biopharmaceutical market. The company's commitment to compliance and adaptability in the face of geopolitical tensions has been well-received by investors, as evidenced by the significant stock price surge.\nThe Hong Kong Stock Exchange saw broad gains on Thursday, with the Hang Seng Index climbing 2.82% to 22,736.87 points, boosted by a rally in tech and e-commerce stocks. WUXI BIO's strong performance contributed to the positive sentiment in the market.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":1,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1173776535"}